Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 9Neoplasms 7Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 5Recurrence 4Prostatic Neoplasms 4Melanoma 4Breast Neoplasms 4Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Head and Neck Neoplasms 3Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycystic Ovary Syndrome 2Pleural Effusion, Malignant 2Mesothelioma, Malignant 2Leukemia, Lymphocytic, Chronic, B-Cell 2Anxiety Disorders 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Rare Malignant Neoplasm 1Pancreatic Neoplasms 1Neuroblastoma 1Nephrotic Syndrome 1Neoplasms, Plasma Cell 1NSCLC 1Myeloproliferative Disorders 1Multiple Myeloma 1

Interventions

Adalimumab 19Etanercept 16Methotrexate 11Infliximab 8tocilizumab 7Rituximab 7golimumab 6Abatacept 6tofacitinib 5Tumor Necrosis Factor Inhibitors 5olokizumab 4Certolizumab Pegol 4Antirheumatic Agents 3Saline Solution 2RC-18 2Nivolumab 2Leflunomide 2veltuzumab 1upadacitinib 1secukinumab 1sarilumab 1mavrilimumab 1entecavir 1cabozantinib 1baricitinib 1andecaliximab 1Vitamin D 1Vaccines 1TACI receptor-IgG Fc fragment fusion protein 1Syringes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Arthritis, Rheumatoid × Pharmaceutical Preparations × Clear all
NCT00035334 2006-02-14

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Bellus Health Inc. - a GSK company

Phase 2/3 Completed
150 enrolled
GastrointestinalGenitourinaryPlasma cell

Amyloidosis, Arthritis, Rheumatoid, Gastrointestinal Diseases, Kidney Diseases, Neoplasm Metastasis, Nephrotic Syndrome, Familial Mediterranean Fever

Data powered by HemOnc (CC BY 4.0) Colophon âš¡